HIV/AIDS Drug Development
NNRTI derivatives more potent against HIV-1 than efavirenz
Published in AIDS Weekly, May 9th, 2005
According to recent research from Japan, "In a previous study, we described the structure-activity relationships (SARs) for a series of thiazolidenebenzenesulfonamide derivatives.
"These compounds were found to be highly potent inhibitors of the wild type (WT) and Y181C mutant reverse transcriptases (RTs) and modest inhibitors of K 103N RT. These molecules are thus considered to be a novel class of non-nucleoside HIV-1 RT inhibitors (NNRTIs)."
"In this paper, we have examined the effects of substituents on both the thiazolidene and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-05-09)
More Articles from AIDS Weekly
- HIV/AIDS Drug Development
High-throughput modified ELISA screens HIV-1 pg41 fusion inhibitors - HIV/AIDS Drug Development
Sulfonated naphthyl porphyrins active against HIV-1 - HIV/AIDS Mental Health
Apathy correlates with cognitive function but not CD4 status in HIV infection - HIV/AIDS Pathogenesis
B30.2(SPRY) domain is the major determinant of anti-HIV-1 potency - HIV/AIDS Vaccine
Anti-HIV Abs induced to control viremia via complement-mediated inactivation - Bioterrorism
Construction company responds to airborne infectious disease isolation needs - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
